The EVALUATION OF RENOPROTECTIVE EFFECT OF CILNIDIPINE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND TYPE 2 DIABETES MELLITUS. A PROSPECTIVE STUDY.

Renoprotective effect of Cilnidipine in patients with mild to moderate Hypertension and Type 2 Diabetes Mellitus.

  • Ramya R Assistant Professor

Abstract

 Objective: The objective of the study was to evaluate the renoprotective effect of cilnidipine by estimating urinary albumin and creatinine levels in mild-to-moderate hypertension (HTN) with type 2 diabetes mellitus (DM) and also evaluate the adverse drug profile of cilnidipine in the same patients.


Methods: This was a single-center, prospective, open-labeled, randomized study. A total of 60 patients of either gender aged between 30 and 60 with mild-to-moderate HTN with type 2 DM were included in the study. Urine albumin and urine creatinine were measured at day 1 and day 181. Blood pressure (BP) was measured in all visits. The drug cilnidipine at a dose of 10–20 mg oral was given and the corresponding improvement in the levels of urine albumin and other parameters was identified.


Results: There was a significant reduction in the mean systolic BP from 150.07±5.44 mmHg in visit 0 to 123.03±5.23 mmHg in visit 3. And also, there was a significant reduction in the mean diastolic BP from 95.5±8.15 mmHg in visit 0 to 80.8±2.42 mmHg in visit 3. The mean heart rate at visit zero was 76.71±4.86. At the end of 6 months of treatment, there was a significant reduction to 70.63±2.74. There was a significant reduction in the microalbuminuria from 66.62±8.39 to 38.8±6.45. The mean reduction was 27.56±10.25. There was no change in the creatinine level.


Conclusion: The study reveals that the drug cilnidipine is safe and effective in reducing the microalbuminuria and also effectively reduces BP in hypertensive patients. Hence, the drug cilnidipine can be safely administered to the patient with diabetes and HTN.

Keywords: KEYWORDS Cilnidipine, Renoprotective, microalbuminuria, Hypertension, Diabetes mellitus

References

1. The National High Blood Pressure Education Program Working Group.
National high blood pressure education program working group report
on hypertension in diabetes. Hypertension 1994;23:145-58.
2. UK Prospective Diabetes Study Group. Tight blood pressure control
and risk of macrovascular and microvascular complications in type
2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ
1998;317:703-13.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk
factors, and 12-yr cardiovascular mortality for men screened in the
multiple risk factor intervention trial. Diabetes Care 1993;16:434-44.
4. Hu G, Jousilahti P, Tuomilehto J. Joint effects of history of hypertension
at baseline and Type 2 diabetes at baseline and during follow-up on the
risk of coronary heart disease. Eur Heart J 2007;28:3059-66.
5. Minami J, Ishimitsu T, Kawano Y, Numabe A, Matsuoka H. Comparison
of 24-hour blood pressure, heart rate, and autonomic nerve activity in
hypertensive patients treated with cilnidipine or nifedipine retard. J
Cardiovasc Pharmacol 1998;32:331-6.
6. Adake P, Somashekar HS, Mohammed Rafeeq PK, Umar D,
Basheer B, Baroud K. Comparison of amlodipine with cilnidipine on
antihypertensive efficacy and incidence of pedal edema in mild to
moderate hypertensive individuals: A prospective study. J Adv Pharm
Technol Res 2015?6:81-5.
7. Xu GL, Hui X, Wu HD, Ling Q. A meta-analysis of the efficacy and
safety of cilnidipine in Chinese patients with mild to moderate essential
hypertension. Afr J Pharm Pharmacol 2012?6:2393-9.
8. Kojima S, Shida M, Yokoyama H. Comparison between cilnidipine and
amlodipine besilate with respect to proteinuria in hypertensive patients
with renal diseases. Hypertens Res 2004;27:379-85.
9. Tsuchihashi T, Ueno M, Tominaga M, Kajioka T, Onaka U, Eto K,
et al. Anti-proteinuric effect of an N-type calcium channel blocker,
cilnidipine. Clin Exp Hypertens 2005;27:583-91.
10. Tanaka M. The L/N-type calcium channel blocker, cilnidipine, reduces
heart rate and albuminuria in patients with Type 2 diabetes. J Int Med
Res 2010;38:602-10.
11. Das A, Kumar P, Kumari A, Chandra S, Gari M, Singh N, et al. Effects
of cilnidipine on heart rate and uric acid metabolism in patients with
essential hypertension. Cardiol Res 2016;7:167-72.
12. Soeki T, Kitani M, Kusunose K, Yagi S, Taketani Y, Koshiba K.
Renoprotective and antioxidant effects of cilnidipine in hypertensive
patients. Hypertens Res 2012;35:1058-62.
13. Singh VK, Mishra A, Gupta KK, Misra R, Patel ML, Shilpa. Reduction
of microalbuminuria in type-2 diabetes mellitus with angiotensinconverting
enzyme inhibitor alone and with cilnidipine. Indian J
Nephrol 2015;25:334-8.
14. Shajahan OM, Rajaram S, Ramya R, Ranga Bhashyam SR. A
comparative study on efficacy and safety of amlodipine and cilnidipine
in the treatment of mild to moderate essential hypertension. Natl J Basic
Med Sci 2020;10:112-23.
Statistics
8 Views | 15 Downloads
How to Cite
R, R. “The EVALUATION OF RENOPROTECTIVE EFFECT OF CILNIDIPINE IN PATIENTS WITH MILD TO MODERATE HYPERTENSION AND TYPE 2 DIABETES MELLITUS. A PROSPECTIVE STUDY. : Renoprotective Effect of Cilnidipine in Patients With Mild to Moderate Hypertension and Type 2 Diabetes Mellitus.”. Asian Journal of Pharmaceutical and Clinical Research, Vol. 14, no. 1, Jan. 2021, pp. 144-6, https://innovareacademics.in/journals/index.php/ajpcr/article/view/39962.
Section
Original Article(s)